menu
    • menu
    [{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Transposon Therapeutics

    Menu

    Transposon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Transposon Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Transposon Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPN-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Transposon Announces Phase 2 Results for TPN-101 in Progressive Supranuclear Palsy

                            Details : TPN-101 is a LINE-1 reverse transcriptase inhibitor. It is being evaluated for progressive supranuclear palsy & C9orf72-related amyotrophic lateral sclerosis and/or frontotemporal dementia.

                            Product Name : TPN-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : TPN-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Transposon Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Transposon Therapeutics

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPN-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Transposon Receives US FDA Fast Track Designation for TPN-101 for Supranuclear Palsy

                            Details : TPN-101 is a LINE-1 reverse transcriptase inhibitor and FDA has granted fast track designation. Currently, it is being evaluated for the treatment of progressive supranuclear palsy.

                            Product Name : TPN-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 21, 2024

                            Lead Product(s) : TPN-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth